Neovacs Logo

Neovacs

Biotech firm developing immunotherapies and investing in BioTech and MedTech.

ALNEV | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0004032746 (+4 more)
LEI:
9695001J9GMM5XYK6482
Country:
France
Address:
14 RUE DE LA REPUBLIQUE, 92150 SURESNES

Description

Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-17 20:00
Levée de fonds de 0,25 MEUR
French 231.5 KB
2025-03-14 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 226.8 KB
2025-03-06 08:00
Sur la base d'une valorisation indépendante de son actif le plus avancé à plus …
French 235.0 KB
2025-03-04 08:00
Néovacs a présenté les derniers résultats de son candidat-vaccin à ARN messager…
French 243.2 KB
2025-02-28 08:00
Ajustement de la valeur nominale
French 214.4 KB
2025-01-21 21:00
Levée de fonds de 0,25 MEUR
French 231.3 KB
2025-01-15 20:00
Ajustement de la valeur nominale
French 210.9 KB
2025-01-10 08:00
L'Agence nationale de la recherche (ANR) soutient le développement d'un vaccin …
French 243.2 KB
2024-12-18 08:30
Levée de fonds de 0,25 MEUR
French 232.4 KB
2024-10-31 18:00
Résultats semestriels 2024
French 264.4 KB
2024-10-18 08:00
Regroupement des actions Néovacs et suspension de la faculté d'exercice des val…
French 235.8 KB
2024-10-11 18:00
Ajustement de la valeur nominale
French 213.9 KB
2024-10-08 08:00
Point sur l'investissement dans Pharnext
French 216.1 KB
2024-09-18 20:00
Levée de fonds de 0,25 MEUR
French 234.8 KB
2024-09-02 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 244.3 KB

Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Neovacs

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Neovacs via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.